Introduction: Bispecific antibodies

Journal of Immunological Methods

Volumn 248, Issue 1-2, 2001, Pages 1-6

  Segal, David M ^a   Weiner, George J ^b   Weiner, Louis M ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BISPECIFIC ANTIBODY; FC RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; IMMUNE RESPONSE; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0035251463     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00338-0     Document Type: Editorial

References (16)

1. Single-chain antigen-binding proteins
2. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin
3. In vivo tumor targeting of a recombinant single-chain antigen-binding protein
4. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors
5. 2 ′ antibody containing thioether-linked Fab′ gamma fragments
6. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli
7. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system
8. Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice
9. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli
10. Formation of a bispecific antibody by the use of leucine zippers
11. Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria
12. Hybrid-hybridomas and production of bi-specific monoclonal antibodies
13. Bispecific antibodies in cancer therapy
14. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene
15. Immunotherapeutic perspective for bispecific antibodies
16. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII